2026 Q1 -tulosraportti
67 päivää sitten
‧1 t 0 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.7. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 6.5. | ||
2026 Q1 -tulosraportti 1.5. | ||
2025 Q4 -tulosraportti 13.2. | ||
Ylimääräinen yhtiökokous 2025 12.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·30.6.Oh yes.. it just keeps going and is going to go up..
I, who knew the technology due to my job, bought long before corona. They have remained. One became ecstatic when they developed the vaccine. Both for the share price and because I felt I was right. But then something happened. Too many projects, I guess, high costs. But it's fun now that it's starting to turn around again. I think they should learn something from this. Vaccines against infections are not the thing. Vaccines against cancer are the thing. They have a very promising program there. I assume that's why it's going up. There's no money in vaccines against various common colds.
·17.6.I believe the journey has only just begun for Moderna. The company has a very broad pipeline with a number of promising projects, including cancer vaccines, which could potentially be revolutionary for the treatment of several forms of cancer. In addition, Moderna is strengthening its presence in Europe by moving parts of the organization here, while also having launched an e-commerce platform. In my assessment, this points to a long-term growth strategy that could bring earnings back towards the levels from the covid period and beyond. At the same time, Moderna builds on patented mRNA technology, where advanced data analysis, pattern recognition, and AI can help accelerate research, development, and identification of new treatment options. This could become a significant competitive advantage in the coming years. And yes, they are also developing the Ebola vaccine
- ·16.6.Is it too late to enter now?I believe the journey has only just begun for Moderna. The company has a very broad pipeline with a number of promising projects, including cancer vaccines, which could potentially be revolutionary for the treatment of several forms of cancer. In addition, Moderna is strengthening its presence in Europe by moving parts of the organization here, while also having launched an e-commerce platform. In my assessment, this points to a long-term growth strategy that could bring earnings back towards the levels from the covid period and beyond. At the same time, Moderna builds on patented mRNA technology, where advanced data analysis, pattern recognition, and AI can help accelerate research, development, and identification of new treatment options. This could become a significant competitive advantage in the coming years. And yes, they are also developing the Ebola vaccine
·22.5.June 1st, 3-6 PM Danish time: Moderna + Merck present KEYNOTE-942 5-year data at ASCO 🔥 It is one of the most important presentations for Moderna's entire cancer pipeline, so keep an extra eye on: • efficacy data and duration • comments on Phase 3 and lung cancer • the market's reaction after the presentation Many investors see it as a potential big stock price trigger for MRNA.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
67 päivää sitten
‧1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·30.6.Oh yes.. it just keeps going and is going to go up..I, who knew the technology due to my job, bought long before corona. They have remained. One became ecstatic when they developed the vaccine. Both for the share price and because I felt I was right. But then something happened. Too many projects, I guess, high costs. But it's fun now that it's starting to turn around again. I think they should learn something from this. Vaccines against infections are not the thing. Vaccines against cancer are the thing. They have a very promising program there. I assume that's why it's going up. There's no money in vaccines against various common colds.
- ·17.6.I believe the journey has only just begun for Moderna. The company has a very broad pipeline with a number of promising projects, including cancer vaccines, which could potentially be revolutionary for the treatment of several forms of cancer. In addition, Moderna is strengthening its presence in Europe by moving parts of the organization here, while also having launched an e-commerce platform. In my assessment, this points to a long-term growth strategy that could bring earnings back towards the levels from the covid period and beyond. At the same time, Moderna builds on patented mRNA technology, where advanced data analysis, pattern recognition, and AI can help accelerate research, development, and identification of new treatment options. This could become a significant competitive advantage in the coming years. And yes, they are also developing the Ebola vaccine
- ·16.6.Is it too late to enter now?I believe the journey has only just begun for Moderna. The company has a very broad pipeline with a number of promising projects, including cancer vaccines, which could potentially be revolutionary for the treatment of several forms of cancer. In addition, Moderna is strengthening its presence in Europe by moving parts of the organization here, while also having launched an e-commerce platform. In my assessment, this points to a long-term growth strategy that could bring earnings back towards the levels from the covid period and beyond. At the same time, Moderna builds on patented mRNA technology, where advanced data analysis, pattern recognition, and AI can help accelerate research, development, and identification of new treatment options. This could become a significant competitive advantage in the coming years. And yes, they are also developing the Ebola vaccine
- ·22.5.June 1st, 3-6 PM Danish time: Moderna + Merck present KEYNOTE-942 5-year data at ASCO 🔥 It is one of the most important presentations for Moderna's entire cancer pipeline, so keep an extra eye on: • efficacy data and duration • comments on Phase 3 and lung cancer • the market's reaction after the presentation Many investors see it as a potential big stock price trigger for MRNA.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.7. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 6.5. | ||
2026 Q1 -tulosraportti 1.5. | ||
2025 Q4 -tulosraportti 13.2. | ||
Ylimääräinen yhtiökokous 2025 12.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 |
2026 Q1 -tulosraportti
67 päivää sitten
‧1 t 0 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.7. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 6.5. | ||
2026 Q1 -tulosraportti 1.5. | ||
2025 Q4 -tulosraportti 13.2. | ||
Ylimääräinen yhtiökokous 2025 12.11.2025 | ||
2025 Q3 -tulosraportti 6.11.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·30.6.Oh yes.. it just keeps going and is going to go up..I, who knew the technology due to my job, bought long before corona. They have remained. One became ecstatic when they developed the vaccine. Both for the share price and because I felt I was right. But then something happened. Too many projects, I guess, high costs. But it's fun now that it's starting to turn around again. I think they should learn something from this. Vaccines against infections are not the thing. Vaccines against cancer are the thing. They have a very promising program there. I assume that's why it's going up. There's no money in vaccines against various common colds.
- ·17.6.I believe the journey has only just begun for Moderna. The company has a very broad pipeline with a number of promising projects, including cancer vaccines, which could potentially be revolutionary for the treatment of several forms of cancer. In addition, Moderna is strengthening its presence in Europe by moving parts of the organization here, while also having launched an e-commerce platform. In my assessment, this points to a long-term growth strategy that could bring earnings back towards the levels from the covid period and beyond. At the same time, Moderna builds on patented mRNA technology, where advanced data analysis, pattern recognition, and AI can help accelerate research, development, and identification of new treatment options. This could become a significant competitive advantage in the coming years. And yes, they are also developing the Ebola vaccine
- ·16.6.Is it too late to enter now?I believe the journey has only just begun for Moderna. The company has a very broad pipeline with a number of promising projects, including cancer vaccines, which could potentially be revolutionary for the treatment of several forms of cancer. In addition, Moderna is strengthening its presence in Europe by moving parts of the organization here, while also having launched an e-commerce platform. In my assessment, this points to a long-term growth strategy that could bring earnings back towards the levels from the covid period and beyond. At the same time, Moderna builds on patented mRNA technology, where advanced data analysis, pattern recognition, and AI can help accelerate research, development, and identification of new treatment options. This could become a significant competitive advantage in the coming years. And yes, they are also developing the Ebola vaccine
- ·22.5.June 1st, 3-6 PM Danish time: Moderna + Merck present KEYNOTE-942 5-year data at ASCO 🔥 It is one of the most important presentations for Moderna's entire cancer pipeline, so keep an extra eye on: • efficacy data and duration • comments on Phase 3 and lung cancer • the market's reaction after the presentation Many investors see it as a potential big stock price trigger for MRNA.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt